Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 7/20 | 0.47 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.46 |
| ▸ | CCKAR | P32238 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517375 | 0.92 | PRMT1 (0.51) | PCSK9ACEEDNRAECE1MAGI3 | |
| SCHEMBL7402043 | 0.89 | MAGI3 (0.57) | PCSK9ACEEDNRAECE1MAGI3 | |
| SCHEMBL7402039 | 0.89 | MAGI3 (0.57) | PCSK9ACEEDNRAECE1MAGI3 | |
| SCHEMBL7402300 | 0.88 | ACE (0.55) | ACEEDNRAECE1MAGI3 | |
| SCHEMBL7402303 | 0.88 | ACE (0.55) | ACEEDNRAECE1MAGI3 | |
| SCHEMBL30517373 | 0.87 | CXCR4 (0.48) | PCSK9IL23RCCKBR | |
| SCHEMBL29417870 | 0.87 | CXCR4 (0.48) | PCSK9IL23RCCKBR | |
| SCHEMBL30517370 | 0.86 | PCSK9 (0.47) | PCSK9MAGI3KMT2AL3MBTL1IL23R | |
| SCHEMBL30725658 | 0.85 | ACE (0.56) | ACEECE1 | |
| SCHEMBL30725660 | 0.85 | IL23R (0.51) | ACEPRMT1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595284-B2 | Amatoxin antibody-drug conjugates and uses thereof | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-04-07 | — | — | US | disclosed |
| US-20260078148-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| US-20230135930-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-05-04 | — | — | US | disclosed |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-114174317-A | Amatoxin antibody-drug conjugates and uses thereof | 海德堡医药研究有限责任公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3958878-A1 | CONDITIONING METHODS FOR GENE THERAPY | Magenta Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-113993550-A | Conditioning method for gene therapy | 美真达治疗公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135930-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MYADM, FUT7, SIGLEC7 | PCSK9 2251/4885ACE 4596/4885EDNRA 2102/4885 |
| US-12595284-B2 | Amatoxin antibody-drug conjugates and uses thereof | HLA-DRB1, CD2, CD74 | PCSK9 4105/4885ACE 4662/4885EDNRA 3107/4885 |
| US-20260078148-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | CD2, CD74, CD99 | PCSK9 3639/4885ACE 4628/4885EDNRA 1733/4885 |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | CD74, CD2, CD44 | PCSK9 4320/4885ACE 4718/4885EDNRA 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.